今日の臨床サポート 今日の臨床サポート
関連論文:
img  25:  Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia.
 
著者: Hélène Pouclet-Courtemanche, Tiphaine Rouaud, Stephane Thobois, Jean-Michel Nguyen, Christine Brefel-Courbon, Isabelle Chereau, Emmanuel Cuny, Philippe Derost, Alexandre Eusebio, Dominique Guehl, Chloé Laurencin, Patrick Mertens, Fabienne Ory-Magne, Sylvie Raoul, Jean Regis, Miguel Ulla, Tatiana Witjas, Pierre Burbaud, Olivier Rascol, Philippe Damier
雑誌名: Neurology. 2016 Feb 16;86(7):651-9. doi: 10.1212/WNL.0000000000002370. Epub 2016 Jan 20.
Abstract/Text OBJECTIVE: To confirm the efficacy and safety of deep brain stimulation (DBS) of the internal part of the globus pallidus in improving severe tardive dyskinesia (TD).
METHODS: Nineteen patients with severe pharmacoresistant TD were included. All were assessed at baseline and at 3, 6 (main outcome measure), and 12 months, and in the long term (6-11 years) for 14 patients, after bilateral pallidal DBS, using motor scales (Extrapyramidal Symptoms Rating Scale [ESRS], Abnormal Involuntary Movement Scale [AIMS]), cognitive scales, and a psychiatric assessment. At 6 months, a double-blind ESRS evaluation was performed in the stimulation "on" and stimulation "off" conditions.
RESULTS: At 6 months, all patients had a decrease of more than 40% on the ESRS. The efficacy of the procedure was confirmed by a double-blind evaluation. This improvement was maintained at 12 months (ESRS: decrease of 58% [21%-81%];
AIMS: decrease of 50% [7%-77%]) and in the long term (ESRS: decrease of 60% [22%-90%];
AIMS: decrease of 63% [14%-94%], n = 14). All the subscores of the ESRS (parkinsonism, dystonia, and chorea) and of the AIMS (facial, oral, extremities, and trunk movements) improved. Despite psychiatric comorbidities at baseline, cognitive and psychiatric tolerability of the procedure was excellent. No cognitive decline was observed and mood was improved in most of the patients.
CONCLUSIONS: Pallidal DBS procedure should be considered as a therapeutic option in disabling TD refractory to medical treatment.
CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with severe pharmacoresistant TD with implanted pallidal leads, the stimulation "on" condition significantly improved ESRS scores compared to the stimulation "off" condition.

© 2016 American Academy of Neurology.
PMID 26791148  Neurology. 2016 Feb 16;86(7):651-9. doi: 10.1212/WNL.0000000000002370. Epub 2016 Jan 20.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから